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The intestinal microbiota is essential to the maturation and homeostasis of the immune system. Immunoblot assays were used to
establish the prevalence of serum IgG, IgM, and IgA antibodies specific for Bifidobacterium adolescentis, Bifidobacterium longum,
and Lactobacillus rhamnosusGGproteins in young children presentingwith or without type 1 diabetes (T1D).We demonstrated that
children between the ages of 6 and 12months had a substantial increase in the frequency of IgG antibodies specific for L. rhamnosus
GG proteins. We measured IgG, IgM, and IgA class antibody reactivity against B. adolescentis DSM 20083, B. adolescentis DSM
20086, and B. longum DSM 20088 proteins demonstrating significantly higher IgA responses against B. adolescentis DSM 20083
strain proteins in children who developed islet autoimmunity and T1D later in life. B. adolescentis strains showed more IgM type
antibodies in children who developed T1D later in life, but the difference was not statistically significant. B. longum proteins were
recognized by IgG and IgA antibodies to a higher extent compared to other bacteria studied.These results confirm that differences
in immune reactivity against some commensal strains in young children may represent a different risk factor for developing T1D.
1. Introduction
Type 1 diabetes (T1D) is characterized by immune-mediated
destruction of the insulin-secreting 𝛽 cells in the pancreatic
islets as a result of an unknown trigger mechanism. It is,
however, well known that development of clinical disease is
preceded by an asymptomatic latent period during which
immune reactions against the insulin-secreting cell autoanti-
gens can be demonstrated [1–3]. In this context, biochem-
ically detectable autoantibodies against insulin (IAA), glu-
tamic acid decarboxylase (GADA), insulinoma-associated
antigen 2 (IA-2A), and Zn-transporter 8 (ZnT8A) as well
as their counterpart immunofluorescent anti-islet antibodies
(ICA) serve as reliable biomarkers for T1D development.
Specifically, Knip et al. [3] demonstrated that all children ini-
tially testing positive for both GADA and IA-2A progressed
to clinical T1D over a 26-year followup.
Over the last few decades the incidence of T1D has dra-
matically increased in many countries particularly in early
childhood, suggesting that an event associated with progres-
sion towards T1D disease was occurring early in life. An
increasing number of studies have suggested that the com-
position of the intestinal microbiota might contribute signif-
icantly to the development of disorders such as T1D since
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changes to themicrofloramirror changes in general life styles
and the social system [4–6].
It is believed that intestinal colonization with certain
bacteria strongly influences systemic immune responses early
in life andmay play a significant role inmodulating the devel-
opment of various chronic diseases [7]. Some of the most
common constituents of the gastrointestinal tract microbiota
include Bifidobacterium and Lactobacillus species that have
been shown to play a significant role in the development of
immune-mediated disorders in humans [8–11]. That is, pre-
dominant colonization with B. adolescentis has been reported
in patients with allergic disorders compared to colonization
patterns observed in individuals with nonallergic disorders
[12–14]. Other Bifidobacterium species have been shown to
have diverse effects, including variable associations of B.
longum with immune-mediated and inflammatory diseases.
Studies of rodent disease models [15, 16] have also identified
differences in the ability of different Bifidobacterium species
in modulating immune reactivity and inflammation. These
observations are in line with study results showing that
different Lactobacillus spp. may have diverse immunomod-
ulating effects on different diseases [17]. Most well known
are the effects of the probiotic strain L. rhamnosus GG in
preventing atopic eczema among infants, possibly by mod-
ulating the immune response to allergens [18]. The recent
identification of the L. rhamnosus GG p40 molecule as an
immunomodulator [19] represents a significant step forward
towards resolving problems related to the effects of probiotics
in vivo.
Previously we demonstrated that the elicitation of anti-
bodies against L. acidophilus antigenic components differed
between children with various chronic diseases [20]. The
current study describes experiments designed to extend these
observations by investigating the prevalence of serum anti-
bodies against B. adolescentis, B. longum, and L. rhamnosus
GG in young children that developed or did not develop T1D.
2. Material and Methods
2.1. Plasma Samples. Plasma samples (𝑛 = 107) from 38 chil-
dren participating in the Finnish Type 1 Diabetes Prediction
and Prevention (DIPP) study and born between 1995 and
2003 were included in this study. Children were separated
into 2 groups of 19 children (11 females) each matched for
age and sex. One group was comprised of children who
later developed at least 2 T1D-related autoantibodies and
subsequently clinical T1D (islet autoimmunity [IA], i.e., the
IA-positive group) and the other group was comprised of
children that did not develop or present with signs of islet
autoimmunity (IA-negative group) and without T1D during
followup. Islet autoimmunity was defined in this context
as detection of at least 2 antibodies out of GADA (assay
sensitivity 82%, specificity 96%), IA-2A (assay sensitivity 72%,
specificity 100%), and/or ICA. Levels of ICA were measured
by an indirect immunofluorescence assay with a detection
limit of 2.5 Juvenile Diabetes Foundation Units. All children
in the IA-positive group later developed T1D (age at onset
ranged between 2.4 and 10.3 years). Both groups were similar
in their documented use of antibiotics (during the first 2
years of life 13/18 IA-positive children and 17/18 IA-negative
children were treated with antibiotics; 𝑃 = 0.177; the data
pertaining to one child from each group was not available).
No differences in the use of probiotics between groups
were observed (2 children from the IA-positive group; 𝑃 =
0.487).
2.2. Bacterial Strains and Cell Lysate Preparation. Wilkins-
Chalgren agar (Oxoid, UK)was used to cultureB. adolescentis
DSM 20083 (ATCC 15703) and DSM 20086 (ATCC 15705)
and B. longum DSM 20088 (ATCC 15697). Man-Rogosa-
Sharpe agar (Oxoid, UK) was used to culture L. rhamnosus
GG. Wilkins-Chalgren agar plates were incubated in an
anaerobic cabinet (Concept, UK; with gas mixture of 5%
CO
2
, 5% H
2
, and 90%N
2
) andMan-Rogosa-Sharpe agar in a
microaerobic environment (Joan, France) with a gas mixture
of 10% CO
2
for 48 h.
Bacterial cells were collected, suspended in phosphate-
buffered saline solution (PBS, pH = 7.4), and washed 3 times
with the same buffer. Subsequently, cells were disrupted
with 0.1mm glass beads (Biospec Products, USA) in PBS
in the presence of complete protease inhibitors (Boehringen
Mannheim-Roche, Switzerland) on ice. The total protein
concentration in lysates was determined using the Protein
Assay solution (Bio-Rad, USA) using bovine serum albumin
as a standard and kept in aliquots at −20∘C until used.
2.3. Gradient Sodium Dodecyl Sulphate Polyacrylamide Gel
Electrophoresis (SDS-PAGE) and 1D Immunoblotting. Equal
amounts of proteins from different Bifidobacteria spp. prepa-
rationsweremixedwith 300𝜇L SDS-PAGE sample buffer and
heated for 15min at 95∘C. To each gel approximately 100 𝜇g of
protein was loaded.
The proteins in the bacterial cell lysate were loaded on
a 5–20% gradient gel with a 5% concentrating gel with All
Blue 10–250 kDa molecular weight (MW) markers (Bio-
Rad, USA) as standards and separated by electrophoresis
using a current of 40mA and a voltage of 200 V for 6 h
using a vertical electrophoresis system SE-600 (Hoefer, USA)
connected to a thermostatic circulator. Separated proteins
were transferred onto a polyvinylidene difluoride (PVDF)
membrane (0.45 𝜇mpore size) using a semidry electroblotter
(Hoefer, USA) at a current density of 1mA/cm2 for 1.5 h and
membranes blocked as described by Nilsson et al. [21].
Five mm wide strips were cut from the membrane and
incubated with plasma samples diluted to 1 : 50 for IgA
and IgM and 1 : 100 for IgG in the incubating buffer [21]
overnight at 4∘C. Strips were then incubated with either
secondary anti-human IgA, anti-human IgM, or anti-human
IgG antibodies labelled with horse-radish peroxidase (HRP)
(diluted 1 : 500; Dako, Denmark) for 1 h and subsequently
developed in substrate solution comprised of 0.04% carbazole
in 50mM sodium acetate buffer (pH = 5.0) and hydrogen
peroxide (0.015%) for 30min at room temperature. All serum
samples were screened in similar fashion. The strips were
scanned using a Bio-Rad GS-710 Imaging densitometer (Bio-
Rad, USA).The relative MWof the bands was estimated with
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Figure 1: IgG, IgA, and IgM reactivity to B. adolescentisDSM 20083
proteins among IA-positive and IA-negative individuals.
the Bio-Rad Quantity One image analysis software (Bio-Rad,
USA) according to the All Blue molecular weight markers.
2.4. Statistical Analysis. The F-test was used to compare the
frequency of antibodies in the two groups. 𝑃 values below
0.05 were considered statistically significant.
3. Results
3.1. IgG Antibody Reactivity to L. rhamnosus GG Proteins. We
first analyzed the dynamics of IgG antibodies that developed
against L. rhamnosusGG target antigens in children between
3 and 24 months of age. This approach was chosen due to
the frequent consumption of the probiotic L. rhamnosusGG-
containing dairy products by children and adults in Finland.
We discovered 25 clearly distinguishable L. rhamnosus GG
antigenic proteins ranging between 11 and 86 kDa (Table 1).
The number of L. rhamnosus GG proteins recognized by
IgG increased steadily with age. Table 2 describes the 9 most
frequently reactive proteins. Children between the ages of 12
and 24 months presented with significantly more antibodies
against 5/9 (31, 42, 45, 47, and 49 kDa proteins) selected
highly reactive proteins compared to reactivity observed in
3-month-old infants. However, no significant differences in
IgG reactivity were observed in response to L. rhamnosusGG
antigens between IA-positive and IA-negative children.
The average number of IgG-reactive L. rhamnosus GG
protein bands was 10.5±6.6 in IA-positive infants (between 5
and 17 bands) and 11.5±7.2 in IA-negative children (between
5 and 20 bands) at 12 months of age. Based on these results
the 12-month-old group was chosen for further analysis of
immune reactivity against Bifidobacterium spp. antigens.
3.2. IgG Reactivity against B. adolescentis and B. longum Pro-
teins. IgG bound to Bifidobacterium antigens in the molec-
ular weight ranging from 7 kDa to 131 kDa. The number of
proteins recognized varied between strains with the greatest
number of reactive antigens observed for B. longum DSM
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Figure 2: IgG, IgA, and IgM reactivity to B. adolescentisDSM 20086
proteins among IA-positive and IA-negative individuals.
IgG and IgA antibodies
N
um
be
r o
f b
an
ds
0
10
20
30
IgG IA+ IgG IA− IgA IA+ IgA IA−
B. longum DSM 20088
P = 0.157
P = 0.061
Figure 3: IgA and IgG reactivity against B. longum DSM 20088
proteins among IA-positive and IA-negative individuals.
20088 (𝑁 = 57; Table 1). The average number of IgG-
reactive proteins in assays with B. adolescentisDSM 20083, B.
adolescentis DSM 20086, and B. longum DSM 20088 strains
was not significantly different between IA-positive children
and IA-negative subjects (Figures 1–3).
3.3. IgA Reactivity against B. adolescentis and B. longum
Proteins. IgA bound to protein antigens in the molecular
weight ranging from 7 kDa to 104 kDa (Table 1). Similar to the
IgG antibody results, more B. longum DSM 20088 proteins
were recognized by IgA than any other tested bacteria. The
average number ofB. adolescentisDSM20083 proteins bound
by IgA was lower than the number of proteins bound from
other strains.Therewas a significant difference in the number
of proteins reactive to antibodies between the 2 groups of
children: 1.9±2.6 reactive protein bands in IA-positive infants
and 1.2 ± 1.2 reactive protein bands in IA-negative children
(𝑃 < 0.003; Figure 1). Also in tests with Bifidobacterium
strains the average number of reacting antigenic proteins
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Table 1: Molecular weight ranges of proteins reacting with IgA and IgG antibodies and the number of detectable antigenic proteins present
in different bacterial homogenates.
Antigenic protein MW ranges Number of reactive antigenic proteins
IgG IgA IgG IgA
L. rhamnosus GG 11–86 kDa n.t.∗ 25 n.t.∗
B. adolescentis DSM 20083 7–80 kDa 7–72 kDa 31 20
B. adolescentis DSM 20086 10–131 kDa 10–92 kDa 36 24
B. longum DSM 20088 10–127 kDa 10–104 kDa 57 44
∗n.t.: not tested.
Table 2: The number of children in different age groups with serum IgG reactivity to different L. rhamnosus GG proteins. The age period
when significantly more (𝑃 < 0.05) antibodies against bacterial proteins were observed compared to the 3-month age group is shown in bold.
L. rhamnosus GG
antigenic proteins
3-month 6-month 12-month 24-month
IA-positive IA-negative IA-positive IA-negative IA-positive IA-negative IA-positive IA-negative
(𝑁 = 18) (𝑁 = 18) (𝑁 = 19) (𝑁 = 19) (𝑁 = 18) (𝑁 = 18) (𝑁 = 15) (𝑁 = 18)
65 kDa 8 (44) 14 (78) 14 (74)∗ 17 (89) 17 (94) 17 (94) 15 (100) 17 (94)
58 kDa 8 (44) 12 (67) 18 (95) 19 (100) 17 (94) 17 (94) 15 (100) 18 (100)
49 kDa 2 (11) 2 (11) 2 (10) 4 (21) 6 (33) 8 (44) 4 (27) 7 (39)
47 kDa 4 (22) 4 (22) 8 (42) 7 (37) 9 (50) 12 (67) 7 (47) 8 (44)
45 kDa 9 (50) 11 (61) 11 (58) 11 (58) 16 (89) 14 (78) 15 (100) 18 (100)
42 kDa 3 (17) 4 (22) 5 (26) 7 (37) 9 (50) 7 (39) 8 (53) 9 (50)
38 kDa 1 (5) 3 (17) 2 (10) 2 (10) 5 (28) 5 (28) 8 (53) 8 (44)
31 kDa 13 (72) 9 (50) 14 (74) 11 (58) 17 (94) 17 (94) 15 (100) 16 (89)
27 kDa 0 (0) 4 (22) 1 (5) 2 (10) 2 (11) 2 (11) 5 (33) 6 (33)
∗Number and % (in brackets) of children with positive reactions to this protein.
tended to be at a higher frequency in the IA-positive group
compared to the IA-negative group (Figures 2 and 3).
3.4. IgM Reactivity to B. adolescentis Proteins. IgM bound
to bacterial proteins in the molecular weight ranging from
13 kDa to 84 kDa. The average number of IgM reacting
protein bands in both assays either with B. adolescentis DSM
20083 or with B. adolescentis DSM 20086 was higher in IA-
positive than in IA-negative infants, but this difference was
not statistically significant (𝑃 = 0.235 and 𝑃 = 0.285, resp.;
Figures 1 and 2).
4. Discussion
This study investigated the reactivity of serum antibodies
against the probiotic strain L. rhamnosus GG and selected
natural Bifidobacterium spp. proteins in children 3, 6, 12,
and 24 months of age using an immunoblot assay developed
previously by our group [20]. L. rhamnosus GG is included
into the most commonly used dairy products in Finland,
whereas all chosen Bifidobacterium strains, B. adolescentis
DSM 20083, B. adolescentisDSM 20086, and B. longumDSM
20088, are usual inhabitants of the intestinal microbiota. The
colonization of newborns with microbes begins during deliv-
ery and by 2 months of age 91% of infants are colonized with
B. longum, 75%withB. adolescentis, and 57%with Lactobacilli
group I (L. rhamnosus, L. casei, and L. paracasei) [10]. A shift
in colonization with B. adolescentis strains towards earlier life
has been demonstrated recently [14] and this has also been
observed at the age of 5 years [13].
The population studied here was obtained from the
Finnish DIPP Study and divided into 2 groups based on the
development of diabetes-associated autoantibodies and T1D
over a 10-year followup. Immunoblot analyses of bacterial
lysates demonstrated a substantial increase in the frequency
of IgG antibody reactivity to L. rhamnosus GG proteins
between 6 and 12 months of age, showing that the most
conspicuous increase in antibody production occurred before
the age of 12months. In spite of these age-dependent changes,
reactions against L. rhamnosus GG proteins were seen in
IA-positive and IA-negative subjects at a similar frequency.
This result indicated that IgG antibodies reactive to probiotic
strain L. rhamnosus GG proteins were not suggestive of
progression toward 𝛽-cell autoimmunity or development of
T1D in children.Themost important observation made from
immunoblot assays testing antibody reactivity to L. rham-
nosus GG proteins was the age-related dynamics associated
with the development of circulating antibodies to microbial
proteins. This emphasized how important it was to carry out
these analyses using Bifidobacterium spp. proteins since these
organisms are known to colonize the infant’s gut early in life.
We assessed binding to different antigenic proteins from B.
adolescentis DSM 20083, B. adolescentis DSM 20086, and B.
longumDSM20088 by IgG, IgA, and IgMclass antibodies and
observed that IgA bound significantly more B. adolescentis
DSM 20083 strain antigens in children who developed islet
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autoimmunity and T1D later in life. At the same time we
could not find any significant differences between the two
groups of children in the frequencies of IgG or IgA antibodies
against other bifidobacteria strains. It is noteworthy that we
found that B. longum proteins were recognized by IgG and
IgA antibodies to a substantially higher extent compared
to other bacteria studied. This phenomenon may indicate
a stronger stimulation of the infant’s immune system by B.
longum protein antigens.
Some of the immunoreactive bands detected may be due
to cross-reactive antibodies that developed in response to
bacterial antigens from species not used in this study. It
is however very difficult to make this distinction since we
presently have no tools (monoclonal antibodies) to discrim-
inate between strain-specific reactivity and cross-reactivity.
Regardless, it was clear that differences in the development
of IgA antibodies with reactivity against B. adolescentis DSM
20083 (ATCC 15703) antigens were present independent of
the mechanism involved. It is of particular importance to
note that differences between the 2 groups were associated
with reactivity by IgA but not IgG or IgM class antibodies.
IgA with reactivity against commensal intestinal microbes
can develop as a consequence of colonization with high num-
bers of organisms at the mucosal surface [22]. It has been
shown that oral administration of the probiotic mixture
VSL#3 that includes 8 different probiotic strains (includ-
ing 3 bifidobacteria strains) prevented the development
of autoimmune diabetes in nonobese diabetic mice [23].
Different bifidobacteria strains have clearly been shown to
have variable influences on immune responses [23, 24]. The
species of B. adolescentis most commonly isolated from
allergic children has been shown to more effectively trigger
the production of proinflammatory cytokines compared to
other strains of bifidobacteria [25, 26] supporting our results
that demonstrated differences between children with and
without signs of𝛽-cell autoimmunitywith regard to reactivity
to B. adolescentis strain 20083 antigens which might impact
T1D development.Whether these differences are in someway
linked to differences in the microbiome needs further studies
[27, 28].
In conclusion, during the first year of life the immune
system starts to produce antibodies which recognize antigens
produced by organisms comprising the normal microbiota.
Although some of these proteins may contain common anti-
genic epitopes present on proteins produced by various bac-
teria, our current study showed that differences in antibody
reactivities could be found even between the same species of
B. adolescentis. These differences might reflect a propensity
for developing T1D confirming recent findings regarding dif-
ferences in the gutmicrobiome between children affected and
unaffected by T1D. Further studies will be needed to verify
how the presence of this particularB. adolescentisDSM20083
strain in the intestine of children is involved in predisposing
individuals to developing 𝛽-cell autoimmunity and T1D.
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